PROCEPT BioRobotics Completes Enrollment in Key Prostate Cancer Study, Gains FDA Approval for New Trial
PRCT sits 37% above its 52-week low of $19.35.
Summary
PROCEPT BioRobotics has completed enrollment for its WATER IV RP study, which compares Aquablation therapy to radical prostatectomy for prostate cancer. This is a significant milestone for the company's expansion into the prostate cancer market beyond its current BPH focus. Additionally, the company received FDA IDE approval for a second WATER IV AS study, evaluating Aquablation therapy against active surveillance for lower-risk prostate cancer. While primary endpoint results for the WATER IV RP study are expected in spring 2027, these advancements position the company for potential long-term growth in a larger addressable market.
At the time of this announcement, PRCT was trading at $26.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $19.35 to $66.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.